Ductal Carcinoma in Situ

Article

A 57-year-old patient presents for evaluation of right nipple discomfort. The patient has family history of a mother and sister with premenopausal breast cancer.

Clinical History

A 57-year-old patient presents for evaluation of right nipple discomfort. The patient has family history of a mother and sister with premenopausal breast cancer.

Findings

Digital mammography shows area of calcifications (Figure 1a-b). Magnification views demonstrate intraductal pleomorphic microcalcifications in the right 11:00 area (Figure 1c).

No noted findings on physical exam or ultrasound.

Diagnosis

Vacuum assisted stereotactic needle core biopsy of the right breast 11:00 microcalcifications reveals ductal carcinoma in situ.

MRI imaging performed for extent of disease demonstrates linear beaded enhancement extending from nipple posteriorly for 8cm within the right breast upper outer quadrant (Figure 2a-b).
 

Discussion

This case demonstrates the benefit of multimodality imaging including digital mammography and breast magnetic resonance imaging (MRI) in this patient, which led to a diagnosis of ductal carcinoma in situ (DCIS). There has been some conflicting information in the literature regarding MRI and its usefulness in the evaluation of DCIS. For this patient, the MRI revealed the extensive area of involvement more so than mammography. This information was critical to the surgeon for surgical planning.

This article was originally published at Diagnostic Imaging

Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
Related Content